Suchergebnisse - "Tavakolpour, Soheil"

PubPharm (6)

1

Rituximab monotherapy in mild pemphigus

enthalten in: The Journal of dermatological treatment | 2022

von Nili, A. | Mahmoudi, H. | Heidari, N. | +4

2

Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment : a case series of 13 patients

enthalten in: The Journal of dermatological treatment | 2022

von Kianfar, N. | Dasdar, S. | Mahmoudi, H. | +3

3

A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus : special focus on COVID-19 pandemic concerns

enthalten in: Immunopharmacology and immunotoxicology | 2021

von Tavakolpour, S. | Aryanian, Z. | Seirafianpour, F. | +6

4

Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases : A retrospective cohort study

enthalten in: Journal of the American Academy of Dermatology | 2021

von Mahmoudi, H. | Farid, A. | Nili, A. | +9

5

Rituximab in practice : Clinical evaluation of patients with pemphigus after rituximab administration

enthalten in: Dermatologic therapy | 2021

von Mahmoudi, H. | Tavakolpour, S. | Balighi, K. | +4

6

Paradoxical reaction to rituximab in patients with pemphigus : a report of 10 cases

enthalten in: Immunopharmacology and immunotoxicology | 2020

von Nili, A. | Tavakolpour, S. | Mahmoudi, H. | +3

CommentOn: Int Immunopharmacol. 2019 Jun;71:40-42. - PMID 30877872

1
[1]